MEDINNOVATE - Key Persons

Andy Black graduated in medicine and surgery from Guy's Hospital, London in 1989 and became a Fellow of the Royal College of Surgeons of England in 1993. Between 1990-1994, Andy practised as a surgeon in various academic hospitals in London and the South East of England, and also worked as a Prosector at the University of Oxford. In 1994, Andy joined the strategy consulting practice of Andersen Consulting where he spent almost 10 years as a consultant in the health and life sciences sector, latterly as a Senior Manager in Accenture's global Health and Life Sciences practice. Andy's principal focus was in supporting the formulation and implementation of R&D operating strategies for major pharmaceutical companies. He also worked closely with major Regulatory Agencies in engagements developing strategy and implementing change in the licensing of pharmaceutical products and their safety evaluation. Of note, Andy was instrumental in the acquisition of the General Practice Research Database (GPRD, now CPRD) by the Medicines and Healthcare products Regulatory Agency (MHRA) and during this time he seconded to the Agency. In 2005, after a period as an independent consultant in which he led the operations of CMR International and supported other pharmaceutical clients, Andy went on to co-found Kinapse and was its Chief Executive until June 2016. Kinapse provides a range of life sciences 'Advise-Build-Operate' services and has grown to a team of c. 700 professionals who serve 16 of the top 20 pharmaceutical companies and the European Medicines Agency from operations in US, Europe and India. Andy remains on the Board of Kinapse as a Non-Executive Director following the acquisition of the business by HgCapital in 2016. Kinapse is one of the UK's life sciences success stories having featured in the Sunday Times Fast Track for several consecutive years as one of the fastest growing and profitable private companies in the UK. Kinapse generated a 16.1X return and IRR of 126% for its previous private equity investor, Synova Capital, at the time of the acquisition by HgCapital. As well as his ongoing advisory role with Kinapse, Andy continues to work actively in the life sciences sector with current engagements including: Advising various Private Equity firms on the life sciences market and potential investments. Mentoring the Chief Executive of a pharmaceutical information and services business Developing the health and life sciences research strategy for a major UK university, focused on forging new strategic partnerships. In addition to his roles at MedInnovate and Kinapse, Andy is the Managing Director of Black Life Sciences Ltd., engages in a range of pro bono consulting for not-for-profit organisations, and has published various thought leadership papers on the strategic development of the life sciences sector.

Fraser Skirrow graduated from Pembroke College Oxford in 1985. After several years with the construction and engineering company Mowlem he entered the MBA programme at London Business School graduating in 1989. He spent 15 years in Andersen Consulting (later Accenture) where he was the partner leading the European R&D consulting business. In 2005 he was a founder member of Kinapse, an international R&D Consulting and outsourcing business. In more than 25 years of consulting he has worked with many of the largest R&D organisations in the world. Typical projects with large pharmaceutical and biotechnology clients include: Post-merger integration. He has led the integration of Development functions in 4 major post-merger assignments each taking 18 months to 2 years, covering multiple sites and countries and several thousand staff. The scope of these projects included development strategy, organisation design, Commercial and Development operations. The aim was to restore performance to pre-merger levels and then create unified, world class development organisations. Operating model design and implementation. He has led design and implementation of new operating models in several global biotechnology and vaccine companies. In general, these were 18 month programmes of analysis, solutions design and implementation that set out the structure for the governance of R&D, the functional and team structures, operating practices, planning and performance management systems and processes. They covered the US and European development hubs and the European commercial operations. Advisory Roles to Senior Development executives. He has supported multiple post-merger integration projects with Kinapse. These were advisory roles with directors of European Development functions on issues including organisation design, performance management, resource management, change management and metrics.

Job Titles:

• Pharmacist
• Chairman of Parafricta Ltd

Maureen, a pharmacist by training, has over 30 years' experience in the life science sector including 25 years at Glaxo companies. She held a variety of leadership roles in R&D, CMC and Clinical Supplies, and supported the Glaxo R&D executive through two major mergers, firstly with Wellcome and later GlaxoWellcome with Smith Kline. On the formation of GSK, she worked in the office of the R&D Chairman as VP, Global R&D Strategy Development working on the early game-changing strategic changes that have since been copied by other organisations (internal R&D business units, competitive external research centres, strategic approach to biological therapeutics, outsourcing R&D). She co-chaired the GSK Innovative Technologies board and was secretary of the Scientific Advisory Board. During this time she represented EU industry in the drafting of the first ICH guidelines on stability testing, and clinical supplies, and the government 25 year strategic review on science. More recently Maureen has been extensively involved with supporting the growth and development of companies large and small. She is currently a business angel and a founding director of MedInnovate. She was founding CEO of NovaThera, a biomaterials and regenerative medicine company spun out from Imperial College London, for which she set the business strategy, raised the funding, recruited the board and leadership team. Novathera merged with Vetcell - a vetinary regenerative medicine company. She was a Non-Executive Director of GW Morocco and Medpharm Ltd- a specialist dermatology company. Maureen was the MedInnovate representative on the Board of Bioanalab which successfully exited to Merck Millipore at a 6.5x ROI. She was a consulting partner at Kinapse Ltd, who provide expert advisory, capability building and operational services to the life sciences industries, where she helped them establish their outsourced pharmaceutical technical documentation offering. Maureen is currently Chairman of Parafricta Ltd which has a range of medical devices protecting fragile skin from friction and shear. She is also Executive Chairman of CNBio Ltd a bioengineering and drug discovery company with world leading human organ -on- chip technologies collaborating with MIT, Imperial College ,Cambridge and Oxford Universties. Maureen was educated in Scotland and graduated from Strathclyde University with a degree in pharmacy and pharmacology. She was the Organon pharmacology prize winner. She is a member of the Academy of Pharmaceutical Scientists. Maureen is a member of a number of women's executive networks and a keen supporter and mentor to women developing their executive careers.

Job Titles:

• Associate Fellow of Green Templeton College
• Chairman of Prescient Healthcare Group, and Oxford Medical Products

Nicholas Edwards graduated in Physiological Sciences from The Queen's College, Oxford in 1982 and then completed his training in Clinical Medicine (BM, BCh) at Green College (now Green Templeton College), Oxford in 1985. After research into the use of Artificial Intelligence to perform medical diagnosis, he completed house jobs in Cardiology and General Surgery before joining Andersen Consulting in 1986. He spent 18 years with Andersen Consulting (now known as Accenture), including 8 years as a partner, and was the global leader of Accenture's Pharmaceutical R&D business. Helping to build a global, world class drug development function from businesses based in Germany, France and the United States. Developing a drug research strategy for a major pharmaceutical company with centres on multiple sites to ensure that they worked together to a unified vision. Supporting the Head of Development to create an integrated organisation after the merger of two large pharmaceutical companies. Nicholas Edwards graduated in Physiological Sciences from The Queen's College, Oxford in 1982 and then completed his training in Clinical Medicine (BM, BCh) at Green College (now Green Templeton College), Oxford in 1985. After research into the use of Artificial Intelligence to perform medical diagnosis, he completed house jobs in Cardiology and General Surgery before joining Andersen Consulting in 1986. He spent 18 years with Andersen Consulting (now known as Accenture), including 8 years as a partner, and was the global leader of Accenture's Pharmaceutical R&D business. Typical projects with global pharmaceutical companies included : Helping to build a global, world class drug development function from businesses based in Germany, France and the United States. Developing a drug research strategy for a major pharmaceutical company with centres on multiple sites to ensure that they worked together to a unified vision. Supporting the Head of Development to create an integrated organisation after the merger of two large pharmaceutical companies. Developing a strategy to achieve dominance in the oncology marketplace for a company with several oncology products. In 2001 he was part of the corporate strategy team for Andersen Consulting developing strategy for the global business and supporting the IPO on the NY Stock Exchange and the rebranding to Accenture. In 2005, he was one of the founders of Kinapse, a business focused on providing consulting and outsourcing services to the pharmaceutical industry. He was Chairman of this business from its foundation until it was sold to Hg Capital in February 2016. He supported its growth into a £27m revenue business employing over 500 people. This delivered a 75x return for the initial investors and a 16x return for Synova Capital who had invested in 2012. He completed consulting projects for Kinapse such as : Supporting the UK Department of Health in understanding the attractiveness of the UK as a centre for commercial clinical research. Helping the CEO and CFO of a Contract Research Organisation identify strengths and weaknesses of their organisation and develop a strategy for growth. He has been an investor and supporter of several life science start-up businesses. This has included providing advice and support to the leadership of each business. Nicholas is part of the Kilfinan Group - a network of senior business people who provide free and informal mentoring to charity chief executives. Nicholas is an Associate Fellow of Green Templeton College, Oxford. He previously chaired the Wealth Creation Oversight Committee of the Oxford Academic Health Science Network. He was for seven years Chairman of Oxtex (developing a surgical implant device for skin expansion). He currently chairs Prescient Healthcare Group (a specialty biopharmaceutical product strategy consultancy) and Oxford Medical Products (developing an anti-obesity treatment).